Proteomic Differences in 3D vs 2D Ovarian Cancer Models and Carboplatin Response

Study Background and Research Question

High-grade serous ovarian carcinoma (HGSOC) remains the most common and lethal subtype of ovarian cancer, with a global annual incidence exceeding 300,000 cases and significant mortality rates. Despite advances in cancer research, most HGSOC patients present with metastatic disease and limited curative options. Platinum-based DNA synthesis inhibitors, notably carboplatin, are foundational in preclinical oncology research and clinical treatment; however, intrinsic and acquired drug resistance continue to undermine long-term outcomes. Traditional drug discovery and biomarker identification predominantly utilize two-dimensional (2D) monolayer cultures, but these models fail to replicate the intricate cell–cell and cell–extracellular matrix interactions present in vivo, potentially skewing observed responses to chemotherapeutics. The central research question addressed in the reference study is how culture dimensionality (2D vs 3D) affects the proteomic landscape of HGSOC cells and their response to carboplatin.

Key Innovation from the Reference Study

The key innovation lies in a comprehensive, quantitative proteomic comparison of HGSOC cell lines cultured in 2D monolayers versus 3D spheroid models. Using isobaric labeling and high-resolution mass spectrometry, the authors systematically profiled global protein expression across four ovarian cancer cell lines (PEO1, PEO4, UWB1.289, UWB1.289+BRCA1), including pairs with matched genetic backgrounds but differing in BRCA status. This approach enabled the identification of 371 proteins that were significantly and commonly altered by culture dimensionality, with particular emphasis on membrane-associated proteins, energy metabolism, and drug resistance pathways. Notably, the study directly links these proteomic shifts to altered responses to carboplatin, a platinum-based DNA synthesis inhibitor critical in both preclinical and translational oncology workflows.

Methods and Experimental Design Insights

The investigators selected four well-characterized HGSOC cell lines: PEO1 and PEO4 (derived from the same patient, pre- and post-platinum resistance, both harboring BRCA2 mutations), and UWB1.289 with its BRCA1-restored derivative. Each line was cultured in both standard 2D conditions and as 3D spheroids, the latter providing a physiologically relevant microenvironment that better recapitulates in vivo tumor architecture. Protein extraction was followed by isobaric tagging and tandem mass spectrometry, resulting in quantification of over 6,400 proteins. Statistical analyses identified proteins consistently and significantly regulated between 2D and 3D formats, with downstream pathway enrichment and network analyses to interpret functional implications. The study also evaluated the impact of these proteomic differences on carboplatin sensitivity, focusing on clinically relevant concentrations and resistance-associated markers.

Core Findings and Why They Matter

The study revealed several critical findings with broad implications for ovarian carcinoma cell proliferation inhibition and platinum-based drug research:

• Dimensionality-Dependent Proteomic Shifts: Of the quantified proteome, 371 proteins exhibited significant, common regulation between 2D and 3D cultures. Proteins upregulated in 3D spheroids were enriched for transmembrane transport functions (notably NADH:ubiquinone oxidoreductase complex I) and energy metabolism pathways, while many membrane-associated proteins were downregulated, with the epidermal growth factor receptor (EGFR) notably suppressed in PEO1 spheroids (reference study).
• Impact on Carboplatin Response: 3D culture conditions induced increased expression of drug resistance–associated proteins, including multiple NDUF family members, thought to contribute to platinum-based chemoresistance. The findings suggest that commonly used 2D models may underestimate resistance mechanisms, underscoring the importance of adopting 3D formats for preclinical oncology research focused on DNA synthesis inhibitor efficacy.
• BRCA Status and Proteomic Context: The paired cell lines allowed dissection of how BRCA1/2 mutations and restoration affect proteomic adaptation and drug response, revealing that both genetic background and microenvironmental context (2D vs 3D) are critical in determining chemotherapeutic outcomes for platinum-based agents.

Together, these insights advance the field by demonstrating that culture dimensionality is not a trivial variable, but fundamentally alters the molecular determinants of carboplatin response and resistance, with direct relevance to translational model selection and drug screening workflows.

Comparison with Existing Internal Articles

The conclusion that 3D culture models more accurately reflect mechanisms of drug resistance in ovarian and other cancers aligns with emerging research in related domains. For example, the article "IGF2BP3–FZD1/7 Axis Drives Carboplatin Resistance in TNBC Stem Cells" identifies a molecular pathway by which platinum-based DNA synthesis inhibitors, including carboplatin, encounter resistance in triple-negative breast cancer stem cells. Both studies converge on the principle that cellular context (whether microenvironmental or molecular) is pivotal for understanding and overcoming chemoresistance. Similarly, the piece "Carboplatin in Preclinical Oncology: Proteomic Insights and 3D Models" advocates for integrating 3D models and proteomic analysis to reveal new targets in ovarian and lung cancer, reinforcing the practical value of the reference study's approach. These internal resources collectively highlight the necessity of adopting advanced in vitro models and systems-level analyses to refine drug efficacy testing and resistance prediction.

Limitations and Transferability

While the reference study provides a robust proteomic dataset and compelling evidence for dimensionality-dependent drug response, some limitations warrant consideration. The analysis is restricted to four HGSOC cell lines, which—although genetically informative—do not capture the full heterogeneity of primary tumors. The study focuses on protein-level changes and does not directly link these to transcriptomic or functional readouts in patient-derived models. Furthermore, while upregulation of resistance-associated proteins in 3D cultures is demonstrated, causal relationships between these molecular changes and clinical carboplatin resistance remain to be validated in vivo. Nevertheless, the findings are highly transferable to preclinical oncology research, especially in experimental design for ovarian carcinoma cell proliferation inhibition and drug screening using platinum-based DNA synthesis inhibitors.

Protocol Parameters

• 3D Spheroid Formation: Seed HGSOC cells in ultra-low attachment plates (typically 2,000–5,000 cells/well) and culture for 5–7 days to form spheroids, ensuring consistent aggregate size for proteomic and drug response assays (reference study).
• Carboplatin Exposure: Treat both 2D and 3D cultures with clinically relevant carboplatin concentrations (e.g., 2.2–116 μM, as supported by product information), and assess viability or proteomic readouts after 24–72 hours of exposure.
• Protein Extraction for Proteomics: Use lysis buffers compatible with isobaric labeling mass spectrometry. Quantify total protein content prior to labeling, and include appropriate normalization controls to account for dimensionality-dependent extraction differences.

Research Support Resources

To enable similar workflows in cancer research, researchers may utilize Carboplatin (SKU A2171), a well-characterized platinum-based DNA synthesis inhibitor suitable for cell proliferation and cytotoxicity assays in both 2D and 3D formats. Detailed handling and solubility guidance are provided in the product documentation to support reproducibility in preclinical oncology studies. For further strategic perspectives on experimental design and overcoming chemoresistance, internal articles such as Unlocking the Next Frontier in Cancer Research offer integrative workflows for translational researchers.